BCAL Diagnostics Limited announced that it has commenced collecting samples for the first stage of its Australian clinical program, to be used for validation and performance evaluation of its blood-based test for detection of breast cancer. In the first instance the test is being trialled for use as an adjunct to mammography, to help improve the accuracy of this commonly used diagnostic approach. This trial will confirm the set of candidate markers used in its breast cancer diagnostic test to distinguish between healthy women and those affected with breast cancer, as well as informing the design of the following pivotal clinical trial which will underpin regulatory approval.